Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas
William D. Tap, Andrew J. Wagner, Patrick Schöffski, et al.
JAMA (2020) Vol. 323, Iss. 13, pp. 1266-1266
Open Access | Times Cited: 236

Showing 1-25 of 236 citing articles:

Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Zhenling Liu, Huanhuan Chen, Lili Zheng, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 517
A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons
Javier Martín‐Broto, José L. Mondaza-Hernández, David S. Moura, et al.
Cancers (2021) Vol. 13, Iss. 12, pp. 2913-2913
Open Access | Times Cited: 107
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 91
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
Patricia Pautier, Antoîne Italiano, Sophie Piperno‐Neumann, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 8, pp. 1044-1054
Closed Access | Times Cited: 85
Hypoxia signaling in cancer: Implications for therapeutic interventions
Yan Zhuang, Kua Liu, Qinyu He, et al.
MedComm (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 60
Anthracycline-induced cardiotoxicity — are we about to clear this hurdle?
Wolfram Dempke, Rafał Zieliński, C. Winkler, et al.
European Journal of Cancer (2023) Vol. 185, pp. 94-104
Open Access | Times Cited: 52
Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma
Patricia Pautier, Antoîne Italiano, Sophie Piperno‐Neumann, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 9, pp. 789-799
Closed Access | Times Cited: 29
Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects
Zhipeng Cao, Sadia Quazi, Sakshi Arora, et al.
Journal of Biomedical Science (2025) Vol. 32, Iss. 1
Open Access | Times Cited: 8
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Jiaojiao Zheng, Siying Wang, Lei Xia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 7
Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma
Seth M. Pollack, Mary W. Redman, Kelsey K. Baker, et al.
JAMA Oncology (2020) Vol. 6, Iss. 11, pp. 1778-1778
Open Access | Times Cited: 102
British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice
Jo Morrison, Janos Balega, Lynn Buckley, et al.
European Journal of Obstetrics & Gynecology and Reproductive Biology (2021) Vol. 270, pp. 50-89
Open Access | Times Cited: 88
Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis
Michael Saerens, Nele Brusselaers, Sylvie Rottey, et al.
European Journal of Cancer (2021) Vol. 152, pp. 165-182
Open Access | Times Cited: 87
British Gynaecological Cancer Society (BGCS) cervical cancer guidelines: Recommendations for practice
Nick Reed, Janos Balega, Tara Barwick, et al.
European Journal of Obstetrics & Gynecology and Reproductive Biology (2020) Vol. 256, pp. 433-465
Closed Access | Times Cited: 78
Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review
Matthieu Roulleaux Dugage, Elise F. Nassif, Antoîne Italiano, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 61
Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond
Axel de Bernardi, Armelle Dufresne, Florence Mishellany, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 1064-1064
Open Access | Times Cited: 51
Cancer cells reprogram to metastatic state through the acquisition of platelet mitochondria
Wenkan Zhang, Hao Zhou, Hengyuan Li, et al.
Cell Reports (2023) Vol. 42, Iss. 9, pp. 113147-113147
Open Access | Times Cited: 30
Therapeutic advances in leiomyosarcoma
Kristine Peregrino Lacuna, Sminu Bose, Matthew Ingham, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 24
Chemotherapeutic drugs for soft tissue sarcomas: a review
Zhichao Tian, Weitao Yao
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 23
Current status of drugs targeting PDGF/PDGFR
Jing-Yan Ai, Chenfu Liu, Wen Zhang, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 7, pp. 103989-103989
Closed Access | Times Cited: 13
Extensive Synergy Between Recombinant Methioninase and Eribulin Against Fibrosarcoma Cells But Not Normal Fibroblasts
Sei Morinaga, QINGHONG HAN, Yutaro Kubota, et al.
Anticancer Research (2024) Vol. 44, Iss. 3, pp. 921-928
Open Access | Times Cited: 9
Sarcomas: Immune biomarker expression and checkpoint inhibitor trials
Mayanne M. T. Zhu, Elahe Shenasa, Torsten O. Nielsen
Cancer Treatment Reviews (2020) Vol. 91, pp. 102115-102115
Open Access | Times Cited: 58
Prognosis of Patients with Metastatic Soft Tissue Sarcoma: Advances in Recent Years
Jakob Lochner, Franka Menge, Nikolaos Vassos, et al.
Oncology Research and Treatment (2020) Vol. 43, Iss. 11, pp. 613-619
Open Access | Times Cited: 51
An urgent call to raise the bar in oncology
John‐John B. Schnog, Michael Samson, Rijk O. B. Gans, et al.
British Journal of Cancer (2021) Vol. 125, Iss. 11, pp. 1477-1485
Open Access | Times Cited: 50
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Albiruni R. Abdul Razak, Sebastian Bauer, Cristina Suárez, et al.
Clinical Cancer Research (2021) Vol. 28, Iss. 6, pp. 1087-1097
Open Access | Times Cited: 49
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
Sandra P. D’Angelo, Allison L. Richards, Anthony P. Conley, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top